TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · IEX Real-Time Price · USD
1.880
+0.010 (0.53%)
At close: May 3, 2024, 4:00 PM
1.960
+0.080 (4.26%)
After-hours: May 3, 2024, 7:52 PM EDT
TherapeuticsMD Revenue
In the year 2023, TherapeuticsMD had annual revenue of $1.30M, a decrease of -98.14%. Revenue in the quarter ending December 31, 2023 was $502.00K, a -99.27% decrease year-over-year.
Revenue (ttm)
$1.30M
Revenue Growth
-98.14%
P/S Ratio
16.65
Revenue / Employee
$1,302,000
Employees
1
Market Cap
21.68M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.30M | -68.66M | -98.14% |
Dec 31, 2022 | 69.96M | 67.39M | 2,619.12% |
Dec 31, 2021 | 2.57M | -62.30M | -96.03% |
Dec 31, 2020 | 64.87M | 15.23M | 30.67% |
Dec 31, 2019 | 49.65M | 33.55M | 208.38% |
Dec 31, 2018 | 16.10M | -678.25K | -4.04% |
Dec 31, 2017 | 16.78M | -2.58M | -13.32% |
Dec 31, 2016 | 19.36M | -786.45K | -3.90% |
Dec 31, 2015 | 20.14M | 5.12M | 34.05% |
Dec 31, 2014 | 15.03M | 6.25M | 71.23% |
Dec 31, 2013 | 8.78M | 4.96M | 129.85% |
Dec 31, 2012 | 3.82M | 1.73M | 82.84% |
Dec 31, 2011 | 2.09M | 846.26K | 68.14% |
Dec 31, 2010 | 1.24M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Flora Growth | 76.07M |
Cue Health | 70.94M |
Cumberland Pharmaceuticals | 39.55M |
DermTech | 15.30M |
Synlogic | 3.37M |
NeurAxis | 2.46M |
OncoCyte | 1.50M |
Alaunos Therapeutics | 5.00K |
TXMD News
- 5 weeks ago - TherapeuticsMD Announces Full Year 2023 Financial Results - Business Wire
- 6 months ago - TherapeuticsMD Announces Third Quarter 2023 Financial Results - Business Wire
- 9 months ago - TherapeuticsMD Announces Second Quarter 2023 Financial Results - Business Wire
- 1 year ago - TherapeuticsMD Announces First Quarter 2023 Financial Results - Business Wire
- 1 year ago - TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition - Business Wire
- 1 year ago - TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma - Business Wire
- 1 year ago - TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma - Business Wire
- 1 year ago - TherapeuticsMD Announces Third Quarter 2022 Financial Results - Business Wire